Xinliang Mao
- Hematology top 2%
- Multiple Myeloma Research and Treatments 30
- Molecular Biology top 2%
- Ubiquitin and proteasome pathways 40
- Protein Degradation and Inhibitors 25
- PI3K/AKT/mTOR signaling in cancer 18
- Histone Deacetylase Inhibitors Research 10
- Protein Hydrolysis and Bioactive Peptides 8
- Cancer Research top 5%
- Oncology top 5%
- Cancer-related Molecular Pathways 10
- Toxicology top 2%
-
- Cancer Mechanisms and Therapy 10
Xinliang Mao
144 papers receiving 4.0k citations
Peers
Comparison fields: 5 of 133
- Hematology 534
- Molecular Biology 2.7k
- Cancer Research 534
- Oncology 847
- Toxicology 84
Countries citing papers authored by Xinliang Mao
This map shows the geographic impact of Xinliang Mao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinliang Mao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinliang Mao more than expected).
Fields of papers citing papers by Xinliang Mao
This network shows the impact of papers produced by Xinliang Mao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinliang Mao. The network helps show where Xinliang Mao may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xinliang Mao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 4 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 1 | |
| 7 | 2024 | 3 | |
| 8 | 2023 | 4 | |
| 9 | 2023 | 16 | |
| 10 | 2023 | 40 | |
| 11 | 2021 | 3 | |
| 12 | 2021 | 41 | |
| 13 | 2018 | 33 | |
| 14 | 2014 | 21 | |
| 15 | 2013 | 17 | |
| 16 | 2012 | 26 | |
| 17 | 2010 | 56 | |
| 18 | 2008 | 54 | |
| 19 | 2008 | 52 | |
| 20 | 2008 | 46 |
About Xinliang Mao
Xinliang Mao is a scholar working on Hematology, Aging and Toxicology, having authored 151 papers that have together received 4.1k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (40 papers), Multiple Myeloma Research and Treatments (30 papers), Protein Degradation and Inhibitors (25 papers), PI3K/AKT/mTOR signaling in cancer (18 papers), Histone Deacetylase Inhibitors Research (10 papers), Cancer-related Molecular Pathways (10 papers), Cancer Mechanisms and Therapy (10 papers) and Protein Hydrolysis and Bioactive Peptides (8 papers). The work is most often cited by research in Hematology (534 citations), Molecular Biology (2.7k citations) and Cancer Research (534 citations). Xinliang Mao has collaborated with scholars based in China, Canada and United States. Frequent co-authors include Biyin Cao, Aaron D. Schimmer, Zubin Zhang, Yuanying Zeng, Jingyu Zhu, Gautam Sethi, Ajaikumar B. Kunnumakkara, Kunkun Han, Rose Hurren and Tingjun Hou. Their work appears in journals such as Blood, Journal of Biological Chemistry, Acta Pharmacologica Sinica, Oncotarget and Anti-Cancer Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.